Reproxalap 0.25% ophthalmic solution achieved primary and secondary endpoints in a trial investigating treatment of dry eye disease, Aldeyra Therapeutics announced in a press release.In a double-masked, sequence-randomized, vehicle-controlled crossover clinic…